Galapagos Genomics Partners with Vertex in Gene Function Research | GenomeWeb

NEW YORK, Aug. 22 – Galapagos Genomics is collaborating with Vertex Pharmaceuticals to identify the function of various proteins, the company announced on Wednesday.

Galapagos, a privately held company based in Mechelen, Belgium, will provide Vertex with recombinant adenoviruses via its PhenoSelect expression platform. Vertex plans to use the information to characterize protein activity within targeted biological pathways.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.